Introduction
============

Chronic obstructive pulmonary disease (COPD) is a condition of progressive deterioration of the respiratory system characterized by obstruction of pulmonary airways and decreased airflow. The airflow limitation is usually progressive and associated to an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking ([@b30-copd-3-671]).

COPD consists of two disorders; chronic bronchitis and emphysema. The diagnosis of chronic bronchitis applies to patients who have a chronic productive cough for at least three months of the year in two or more successive years. On the other hand, emphysema is a pathological diagnosis describing permanent abnormal enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of alveolar walls. Most patients have elements of both chronic bronchitis and emphysema in varying degrees, but some may have one without the other ([@b37-copd-3-671]). Although mainly affecting the lungs, it also produces other significant systemic consequences, including skeletal muscle dysfunction, nutritional abnormalities and weight loss, cardiovascular and nervous system abnormalities, as well as osteoskeletal effects ([@b5-copd-3-671]; [@b2-copd-3-671]).

COPD is a major global epidemic affecting 5%--15% of all adults in industrialized countries ([@b122-copd-3-671]), normally presenting after the age of 50. Incidence increases with age, such that 50% of smokers over the age of 65 years are affected ([@b99-copd-3-671]). Using a variety of guides, Linberg and colleagues (2005) reported a prevalence of COPD between 7.6% and 12.2%. In a multicenter epidemiological study carried out in Spain, COPD was found in 15.8% of men and 5.5% of women ([@b124-copd-3-671]).

COPD is a major cause of morbidity, mortality, and disability in the United States. An estimated 10 million adults in this country were diagnosed with COPD in the year 2000 ([@b96-copd-3-671]). It is becoming more common, and accounts for significant and increasing utilization of health care resources ([@b55-copd-3-671]; [@b129-copd-3-671]).

Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by recurrent upper airway collapse during sleep ([@b169-copd-3-671]). The inspiratory efforts to overcome occlusion lead to arousal, sleep fragmentation, and oxyhemoglobin desaturation ([@b42-copd-3-671]). Though clinically recognized for more than two decades ([@b65-copd-3-671]; [@b100-copd-3-671]; [@b72-copd-3-671]), general awareness of OSAS has been slow to develop. In a middle-aged population, [@b169-copd-3-671] found that 2% of women and 4% of men presented OSAS. In our community, there is an OSAS prevalence of 3.4% in men, 3% in women ([@b48-copd-3-671]), and 6.8% among subjects 50--70 years of age ([@b172-copd-3-671]).

OSAS sometimes coexists with COPD. [@b56-copd-3-671] called this combination ''overlap syndrome." We analyze the epidemiology, pathophysiology, and clinical features as well as therapy for overlap syndrome.

Effects of sleep on ventilation
===============================

Human sleep can be divided into two patterns, nonrapid eye movement sleep (NREM) and rapid eye movement sleep (REM), each with distinctive physiological characteristics. The four stages of NREM sleep are categorized by the frequency and amplitude of the electroencephalography (EEG), the presence of sleep spindles and K complexes and electro-oculogram and electromyogram findings. REM sleep is characterized by bursts of rapid eye movement, muscle atonia and shallow and irregular breathing. REM sleep is subdivided into two periods: tonic and phasic. Longer REM periods occur mainly during the last part of nocturnal sleep.

Sleep has profound effects on ventilation ([@b45-copd-3-671]), which are partly attributable to a slight decrease in metabolic rate ([@b47-copd-3-671]; [@b158-copd-3-671]). In fact, the respiratory system is challenged by sleep, and for patients debilitated by respiratory disease, the conditions imposed may become excessive and lead to failure. Furthermore, when respiratory failure is already present during wakefulness, the situation is even more serious during sleep.

We will only briefly summarize the main effects of sleep on ventilation, as comprehensive descriptions already exist ([@b125-copd-3-671]; [@b87-copd-3-671]).

Breathing responses are distinctly different during REM and NREM sleep. There is a significant reduction in minute ventilation, especially during REM sleep, as a result of decreased tidal volume not being fully compensated by an increase in respiratory frequency ([@b13-copd-3-671]). The consequence is a worsening of arterial blood gases with a significant reduction in partial pressure of oxygen in arterial blood (PaO~2~) and an increase in partial pressure of carbon dioxide in arterial blood (PaCO~2~) ([@b24-copd-3-671]). During NREM sleep, gas exchange becomes altered with a decrease is PaO~2~ ([@b112-copd-3-671]), but not as much as during REM sleep.

Compared to wakefulness, ventilatory response to hypercapnia and hypoxia is diminished during NREM sleep and further depressed during REM sleep ([@b46-copd-3-671]; [@b47-copd-3-671]). The ventilatory and arousal responses to hypercapnia are much more robust than for hypoxia, with only slight changes in PaCO~2~ causing recognizable alterations of minute ventilation ([@b111-copd-3-671]).

Decreased muscle tone during sleep increases respiratory resistance and the inability to compensate these changes probably contributes to reduced responses ([@b161-copd-3-671]). During NREM sleep, the phasic electromyographic activity of genioglossus and geniohyoid muscles is well-maintained ([@b11-copd-3-671]), but tonic activity of upper airway dilators decreases ([@b160-copd-3-671]; [@b154-copd-3-671]). During REM sleep, hypotonia of postural muscles, including intercostals muscles and other accessory respiratory muscles, occurs ([@b109-copd-3-671]; [@b163-copd-3-671]), and upper airway resistance increases ([@b8-copd-3-671]).

Lung volume is also reduced during sleep and this is manifested by a reduction in the functional residual capacity (FRC) during NREM sleep ([@b79-copd-3-671]). Several factors, reduction in lung compliance and reduced respiratory muscle tone, have been suggested as potential causal factors in the reduction in FRC ([@b23-copd-3-671]; [@b9-copd-3-671]). It has been hypothesized that reduced FRC during sleep may induce the closure of airways within the regular breath, causing a ventilation--perfusion mismatch, contributing to the small but yet significant changes in arterial saturation seen especially during REM sleep ([@b18-copd-3-671]).

Effects of sleep on ventilation in COPD patients
================================================

The control of breathing in patients with COPD follows the same basic principles as in normal subjects; however, these patients present lower feedback response during sleep. A decrease in oxygen saturation during sleep may appear in normal subjects, as well as COPD patients; however, in the latter it has a much greater effects on arterial blood gases due to the different position of initial PaO~2~ on the O~2~ dissociation curve.

Nocturnal desaturation in COPD patients presents specific characteristics ([Table 1](#t1-copd-3-671){ref-type="table"}). It mainly takes place at the end of the night during REM sleep ([@b27-copd-3-671]) and events may vary considerably from one night to the next, especially in patients with moderate-to-severe COPD ([@b92-copd-3-671]). In addition, these desaturations are significantly related to daytime hypoxemia and hypercarbia ([@b113-copd-3-671]); the more pronounced daytime hypoxemia and hypercapnia, the more severe nocturnal hypoxemia ([@b56-copd-3-671]). Furthermore, COPD patients may require direct assessment of nocturnal desaturation by oximetry, because the degree of hypoxemia during sleep cannot be predicted from measurement of arterial oxygen saturation in individual awake patients.

The main mechanism causing nocturnal desaturations in COPD patients is periodic hypoventilation, which, in turn, is believed to be the result of decreased activity in intercostals muscles and blunted chemical respiratory drive ([@b155-copd-3-671]; [@b78-copd-3-671]). This is especially pronounced in patients with hyperinflated lung ([@b17-copd-3-671]). Another cause of nocturnal desaturations is the worsening of ventilation perfusion mismatching which is related to a decreased functional residual capacity and the dissociation between diaphragmatic and intercostals activity during REM sleep.

Effects of sleep on ventilation in OSAS patients
================================================

During apneas caused by obstruction, the collapsed pharynx impedes airflow in spite of continued effort to breathe. This causes progressive asphyxia, which increasingly stimulates breathing efforts against the collapsed airway, typically until the person is awakened ([@b162-copd-3-671]). Various factors, ranging from upper airway anatomy to central respiratory control mechanisms, interact to produce the clinical syndrome of OSAS. The primary defect is probably an anatomically small or collapsible pharyngeal airway, in combination with a sleep-induced fall in upper airway muscle activity ([@b93-copd-3-671]; [@b61-copd-3-671]). One or more of these variables, which conspire to cause upper airway obstruction ([@b81-copd-3-671]; [@b6-copd-3-671]), may affect any given OSAS patient.

Some studies have shown that ventilatory control is less stable in patients with OSAS, ([@b80-copd-3-671]; [@b168-copd-3-671]), while other authors claim that ventilatory instability alone is not sufficient to produce periodic breathing ([@b157-copd-3-671]). Upper airway resistance in OSAS appears to be influenced by the intensity of the central respiratory drive ([@b145-copd-3-671]).

Abnormal hypoxic and hypercapnic respiratory drive has also been reported in hypercapnic OSAS patients, in contrast to normal hypoxic and hypercapnic respiratory drive in eucapnic patients ([@b64-copd-3-671]; [@b151-copd-3-671]). The role of this reduction in chemical drives is still under discussion. It is not clear whether it is an inherited abnormality in ventilatory control ([@b51-copd-3-671]; [@b131-copd-3-671]), or secondary to sleep apnea as suggested by the improvement in ventilatory response to CO~2~ in hypercapnic OSAS patients after CPAP therapy ([@b16-copd-3-671]; [@b94-copd-3-671]). Lin studied six patients with hypercapnic OSAS and 24 patients with eucapnic OSAS. Both the slope and baseline level of ventilatory response and mouth occlusion pressure improved significantly in hypercapnic patients after two weeks of CPAP therapy ([@b94-copd-3-671]).

Overlap syndrome
================

Physiological consequences
--------------------------

Clinical evidence suggests that the majority of patients with OSAS are eucapnic during wakefulness, and that detection of daytime hypercapnia attests to mechanical impairment of the respiratory system due to obesity and/or COPD ([@b71-copd-3-671]; [@b91-copd-3-671]).

Overlap syndrome predisposes to daytime hypercapnia and hypoxemia independently of lung function ([@b33-copd-3-671]). Nocturnal desaturation severity is related to a specific entity within the wide spectrum of sleep-disordered breathing and the severity of COPD.

It is known that overlap patients present more nocturnal desaturation than patients with either OSAS or COPD alone ([@b34-copd-3-671]; [@b141-copd-3-671]). [@b141-copd-3-671] examined the degree to which COPD and OSAS independently and jointly contribute to desaturation during sleep. After adjusting for confounding factors, the odds ratio for nocturnal oxyhemoglobin desaturation was considerably increased in OSAS patients. [@b14-copd-3-671] compared polysomnographic variables between overlap syndrome and OSAS subjects. The overlap syndrome group had lower mean arterial blood saturation and spent more time in desaturation than the OSAS group. [@b128-copd-3-671] compared the breathing pattern and CO~2~ response in 11 obese male overlap syndrome patients, 20 obese male OSAS patients with normal lung function, and 13 healthy nonobese controls. Overlap patients had a higher breathing frequency and lower tidal volume than OSAS patients. The OSAS group presented similar values to controls in ventilatory response to CO~2~ and occlusion pressure responses. This author concludes that overlap patients with hypercapnia have both blunted ventilatory responses and mouth occlusion pressure responses to CO~2~ ([@b128-copd-3-671]) and that ventilatory response may be disturbed by lung mechanics and gas exchange. In subjects with chronic hypercapnia, there is an increased blood bicarbonate concentration, which may inhibit CO~2~ sensitivity and decreases mouth occlusion pressure response ([@b128-copd-3-671]). Other authors have postulated that hyperinflation of the lung may also decrease mouth occlusion pressure response ([@b54-copd-3-671]).

In patients with overlap syndrome, sleep disordered breathing is associated with upper and lower airway obstruction and a reduction in respiratory drive. Respiratory muscles may also fatigue which is related to the mechanical disadvantage of chest wall hyperinflation. Moreover, there is also a reduction in functional residual capacity which is related to supine posture and sleep state, and a ventilation perfusion mismatch ([Figure 1](#f1-copd-3-671){ref-type="fig"}).

Pulmonary hemodynamics
----------------------

Pulmonary hemodynamic studies during sleep in COPD patients have been scarce probably because its invasive nature is not compatible with normal sleep ([@b156-copd-3-671]).

Alveolar hypoxia is the most important mechanism leading to pulmonary arterial vasoconstriction and pulmonary hypertension ([@b19-copd-3-671]) and COPD is frequently complicated by the development of pulmonary hypertension, which is associated with increased morbidity and mortality ([@b32-copd-3-671]; [@b165-copd-3-671]).

OSAS patients may also present sustained pulmonary hypertension ([@b142-copd-3-671]; [@b138-copd-3-671]; [@b7-copd-3-671]), and the risk increases considerably if it is associated with COPD, obesity or both ([@b20-copd-3-671]; [@b89-copd-3-671]; [@b35-copd-3-671]).

In a group of patients with overlap syndrome, [@b34-copd-3-671] found that the main determinants of pulmonary hypertension were daytime arterial blood gases and FEV~1~. In a study by [@b76-copd-3-671], pulmonary hypertension was found in 13.6% of OSAS patients (related to disease severity and obesity) and in 80% of overlap patients.

Epidemiology
------------

Overlap syndrome has a prevalence of 14% among patients with mild COPD ([@b34-copd-3-671]) and 11% among patients with OSAS ([@b141-copd-3-671]). The prevalence of overlap syndrome is very different depending on the definition used. Some of the apparent discrepancies between studies can be explained by differences in selection criteria, population characteristics and design ([Table 2](#t2-copd-3-671){ref-type="table"}). In early studies, a high prevalence of OSAS was found in individuals with COPD. [@b70-copd-3-671] studied 26 COPD patients while sleeping and found that 92% of all abnormal respiratory events during sleep contained an obstructive component. [@b34-copd-3-671] prospectively investigated 265 OSAS patients and reported that 11% had an obstructive spirographic pattern. [@b133-copd-3-671] retrospectively evaluated data from 213 consecutive patients referred to the Sleep Laboratory, and found that 16% had overlap syndrome. [@b41-copd-3-671] found a 28.5% prevalence of overlap in a group of patients referred to the hospital. However, this high prevalence could well be due to a selection bias. Nevertheless, a very large study including 5,954 participants done in conjunction with the Sleep Heart Health Study, did not find significant differences in the prevalence of OSAS among COPD subjects (14.0%) and those without COPD (18.6%) ([@b141-copd-3-671]). In the study by [@b170-copd-3-671] of 300 patients referred for clinical suspicion of OSAS, 15.4% of patients were classified as overlap. More recently, [@b14-copd-3-671] studied 356 males and 320 females and found overlap syndrome in 9.2% of the OSAS population, while [@b116-copd-3-671] found overlap syndrome in 11.9% of COPD patients.

OSAS, COPD, and cardiovascular risk
===================================

Systemic inflammation is increasingly being recognized as a risk factor for a number of different complications including atherosclerosis ([@b135-copd-3-671]) and is a well-established factor in the pathogenesis of cardiovascular disease (CVD) ([@b73-copd-3-671]). There is growing recognition that COPD is a systemic disease ([@b1-copd-3-671]; [@b166-copd-3-671]) with multiple effects on end-organs including organs in the cardiovascular system ([@b25-copd-3-671]; [@b149-copd-3-671]). The pathophysiology of how COPD increases cardiovascular risk is largely unknown. Several studies have shown that reduced lung function is associated with an increase in a variety of systemic inflammatory markers ([@b143-copd-3-671]; [@b153-copd-3-671]; [@b67-copd-3-671]). [@b63-copd-3-671] conducted a systematic review of studies involving the relationship between COPD, forced expiratory volume in one second (FEV~1~), and levels of various systemic inflammatory markers. Compared to healthy controls, COPD patients were found to have significantly raised levels of C-reactive protein (CRP), fibrinogen, leucocytes, and tumor necrosis factor-alpha (TNF-α). All of which indicate persistent systemic inflammation. This finding may explain, at least in part, the high prevalence of systemic complications (including cardiovascular diseases) among patients with COPD ([@b63-copd-3-671]).

C-reactive protein is an important serum marker of inflammation and an independent predictor of cardiovascular disease ([@b136-copd-3-671]; [@b134-copd-3-671]). CRP is increased in COPD patients and may be a systemic marker of the inflammatory process ([@b22-copd-3-671]; [@b102-copd-3-671]; [@b127-copd-3-671]).

A number of epidemiological studies have shown that OSAS is associated to cardiovascular morbidity ([@b115-copd-3-671]; [@b123-copd-3-671]; [@b12-copd-3-671]; [@b104-copd-3-671]). In this disease, intense local and systemic inflammation occurs. These patients present elevated inflammatory mediators such as TNF-α and interleukin-6 ([@b97-copd-3-671]; [@b26-copd-3-671]; [@b82-copd-3-671]; [@b68-copd-3-671]), leptin ([@b83-copd-3-671]; [@b147-copd-3-671]; [@b74-copd-3-671]; [@b120-copd-3-671]; [@b10-copd-3-671]), and adhesion molecules ([@b118-copd-3-671]; [@b36-copd-3-671]; [@b53-copd-3-671]; [@b49-copd-3-671]; [@b173-copd-3-671]). The levels of these mediators improve with CPAP treatment ([@b75-copd-3-671]; [@b110-copd-3-671]).

As in COPD, patients with OSAS present high levels of CRP, which are related to disease severity ([@b146-copd-3-671]; [@b167-copd-3-671]; [@b86-copd-3-671]; [@b174-copd-3-671]).

Endothelial dysfunction is considered an indicator of myocardial or vascular dysfunction before the emergence of clinical signs of overt cardiovascular disease ([@b28-copd-3-671]). A number of studies involving OSAS patients indicate an associated endothelial dysfunction ([@b114-copd-3-671]; [@b117-copd-3-671]; [@b90-copd-3-671]) which improved after CPAP treatment ([@b84-copd-3-671]). Few studied, however, have focused on the relation between endothelial dysfunction and COPD. [@b29-copd-3-671] evaluated a variety of plasma markers of endothelial dysfunction in 14 COPD patients, finding altered level of tissue factor pathway inhibitor and selectins.

Furthermore, there is evidence of a perturbed neurohumoral regulatory system in COPD patients ([@b62-copd-3-671]; [@b4-copd-3-671]) and OSAS patients ([@b150-copd-3-671]; [@b40-copd-3-671]).

Clinical characteristics
------------------------

The most common symptoms of OSAS patients include chronic loud snoring, excessive daytime sleepiness, personality changes, and deterioration of quality of life ([@b171-copd-3-671]; [@b132-copd-3-671]; [@b126-copd-3-671]). COPD patients, on the other hand, may present cough, sputum production, and/or dyspnea (Celli and Mcnee 2004). Nevertheless, overlap patients present unique characteristics, which set them apart from either COPD or OSAS patients.

A number of studies compare the clinical characteristics of overlap patients to those of OSAS-only patients. [@b34-copd-3-671] found that, compared to the OSAS-only group, the overlap population tended to be older, with more common hypoxemia and hypercapnia, higher mean pulmonary artery pressures, but similar body mass index (BMI). [@b116-copd-3-671] found that overlap patients were older and less obese. Resta and colleagues (2002) showed that overlap patients had higher PaCO~2~, as well as similar apnea--hypoapnea index (AHI). This author developed a model for predicting PaCO~2~ in overlap patients based on PaO~2~, FEV~1~, and weight. However, overlap patients need not be distinctive in all variables. For example, studies by [@b128-copd-3-671] and [@b170-copd-3-671] found no significant differences in OSAS severity, mean arterial oxygen saturation during sleep, and BMI.

Special notice should be taken of [@b85-copd-3-671] suggestion that in OSAS patients exhibiting permanent pulmonary hypertension, bronchial obstruction is generally not severe and the level of hypoxemia and hypercapnia is modest. Therefore, chronic airway obstruction in these patients may be asymptomatic, making it necessary to systematically perform pulmonary function tests in all patients diagnosed with OSAS by polysomnography ([@b85-copd-3-671]).

Quality of sleep
----------------

There is evidence that insomnia and other sleep problems are increased in patients with COPD ([@b39-copd-3-671]). Particularly in elderly COPD patients, sleep quality is decreased in the form of morning tiredness and early awakenings ([@b15-copd-3-671]). In addition, data from sleep studies has shown marked increases in stage changes, frequent arousals and awakenings, long sleep latency, and reduced sleep efficiency ([@b57-copd-3-671], [@b21-copd-3-671]). All these sleep disturbance are likely to have multifactorial origins. Symptoms or comorbid conditions such as nocturnal cough, wheezing, depression, drugs, sedentary lifestyle, and shortness of breath may also contribute ([@b156-copd-3-671]).

In OSAS patients, one of the most incapacitating symptoms is excessive daytime somnolence, which results from disrupted sleep or nighttime oxygen desaturation ([@b38-copd-3-671]; [@b144-copd-3-671]). Nevertheless, COPD patients did not have any significant daytime sleepiness, despite feeling somewhat tired ([@b119-copd-3-671]; [@b137-copd-3-671]).

[@b141-copd-3-671] have observed that COPD-only patients had minimally perturbed sleep. No significant differences were observed in sleep structure with respect to FEV~1~. [@b130-copd-3-671], in a community-based study, showed that sleep structure variables did not change in subjects with a history of lung disease. In addition, they found that sleep stage distributions varied in accordance with AHI level.

Poor-quality sleep may also be associated to hypoxemia and increased superficial sleep ([@b140-copd-3-671]).

Diagnostic procedures
---------------------

The diagnosis of OSAS should be based on clinical findings and confirmed by a full-night polysomnography, which has traditionally been regarded as the gold standard for diagnosis ([@b43-copd-3-671]; [@b59-copd-3-671]; [@b88-copd-3-671]). However, alternatives that are less expensive and time consuming are increasingly becoming popular ([@b58-copd-3-671]; [@b159-copd-3-671]) ([Figure 2](#f2-copd-3-671){ref-type="fig"}).

With respect to COPD, clinical assessment should include questions about sleep quality and possible co-existing OSAS. Polysomnography studies are not indicated in COPD except in special circumstances which include a clinical suspicion of OSAS (hypersomnolence), nocturnal hypoxemia complications unexplained by waking arterial oxygen levels, and pulmonary hypertension that is out of proportion to the severity of pulmonary function derangement ([@b44-copd-3-671]).

Treatment
=========

All patients with OSAS should be counseled about the potential benefits of therapy and the risks of going without therapy. Furthermore, they should be advised of the importance of avoiding factors that increase the severity of upper-airway obstruction such as sleep deprivation, the use of alcohol, hypnotic agents, and increased weight ([@b98-copd-3-671]; [@b77-copd-3-671]). Although CPAP therapy is a well-established, widely used treatment, it is not suitable for all patients ([@b121-copd-3-671]; [@b105-copd-3-671]; [@b66-copd-3-671]).

Conventional O~2~ therapy is prescribed to stable COPD patients who exhibit marked and persistent hypoxemia. This therapy is sufficient for correcting even severe nocturnal desaturation and has favorable effects on the observed hypoxemia related peaks of pulmonary hypertension ([@b60-copd-3-671]). Some authors report that oxygen therapy improves the quality of sleep by shortening latency to sleep, increasing REM sleep as well as stages 3 and 4, and by decreasing number of arousals ([@b69-copd-3-671], [@b24-copd-3-671]). However, discrepant results exists ([@b57-copd-3-671]; [@b107-copd-3-671]), which may be due to differences in the severities of daytime and nighttime hypoxemia, as well as study design.

In some patients, particularly those with hypercapnia, higher oxygen flows may induce further carbon dioxide retention with resultant morning headache and confusion. However, if there is a marked worsening in hypercapnia with oxygen therapy, noninvasive nocturnal ventilation (NIPPV) may be added. Although the precise mechanisms are not yet clear, NIPPV could improve gas exchange in COPD patients by resting the respiratory muscles, resetting the respiratory centers ([@b52-copd-3-671]) and improving respiratory mechanics ([@b148-copd-3-671]). Nevertheless, there are conflicting results regarding the utility of this treatment in long-term COPD, particularly during sleep ([@b164-copd-3-671]; [@b3-copd-3-671]).

Additional treatment options include theophylline, ipratropium bromide tiotropium ([@b101-copd-3-671]; [@b106-copd-3-671]; [@b108-copd-3-671]).

Certain drugs should be administered with caution. Hypnotics, for example, can adversely affect respiration and gas exchange in patients with COPD by decreasing upper airway muscle tone and blunting the respiratory drive ([@b152-copd-3-671]). It is also advisable for COPD patients to avoid alcohol ingestion before sleep because it has been shown to worsen hypoxemia ([@b50-copd-3-671]) or lead to hypercapnic respiratory failure ([@b31-copd-3-671]).

The coexistence of OSAS and COPD defines a group of special risk patients. In these overlap patients, waking and sleep-related hypoxemia and hypoxemic cardiovascular consequences are more marked than in OSAS-only patients.

CPAP has been shown to acutely improve overnight oxygenation in patients with overlap syndrome. In fact, CPAP with supplemental oxygen for correction of upper airway obstructive episodes and hypoxemia during sleep is the treatment of choice for these patients ([@b139-copd-3-671]).

Few studies exist on the long-term effect of CPAP in overlap syndrome. [@b41-copd-3-671] evaluated the effects of CPAP therapy on lung function in patients with overlap syndrome over two consecutive years. After six months of CPAP therapy, there were statistically significant increases in PaO~2~, FEV~1~, and forced vital capacity (FVC). Response of overlap syndrome patients to CPAP therapy was superior in the hypercapnic group, particularly in relation to improvement of arterial blood gases.

[@b103-copd-3-671] evaluated the effects of CPAP on lung function in patients with overlap. Fourteen patients were studied, ten of whom were able to tolerate CPAP for at least three months. Improvement was found in gas exchange and FEV~1~ associated with a decrease in hospitalizations.

CPAP treatment may have other potentially benefits. As COPD is an inflammatory airways disorder, it may be that OSAS acts as an inflammatory stimulus. Thus, the improvement in OSAS resulting from the application of CPAP may, in turn, lead to an improvement in the coexistent COPD. Nevertheless, further study is still needed.

Funding for this study was provided by grants PGIDIT04SIN206003PR and FIS PI051094. The authors report no conflicts of interest in this work.
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###### 

COPD desaturation characteristics

  ------------------------------------------------------------------------------------------------------------------------
  Occurs mainly during REM sleep
  Presents considerable variability in nocturnal desaturation from night to night
  Statistically relationships exist between nocturnal desaturation and daytime hypoxemia and hypercarbia
  Nocturnal desaturarion cannot be predicted from awake measurement of arterial oxygen saturation in individual patients
  ------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; REM, rapid eye movement sleep.

###### 

Prevalence of overlap syndrome in COPD and OSAS patients

  Authors     Number of patients   Sample               Group   Prevalence
  ----------- -------------------- -------------------- ------- ------------
  Chaouat     265                  Sleep Laboratory     OSAS    11%
  Resta       213                  Sleep Laboratory     OSAS    13.6%
  De Miguel   193                  Sleep Laboratory     OSAS    28.5%
  Sanders     1132                 General population   COPD    14%
  Zamarrón    300                  Sleep Laboratory     OSAS    15.4%
  Bednarek    676                  General population   OSAS    9.2%
  O'Brien     120                  Sleep Laboratory     OSAS    11.9%

**Abbreviations:** COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome.
